Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the acquisition of Baxter Healthcare Corporation's Enlon product line, including: Enlon (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial; Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection 5 mL ampule; Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection, 15 mL multi-dose vial.
Bioniche purchased the rights and certain assets related to the Enlon product line from Baxter, which discontinued Enlon in February 2008. Bioniche anticipates launching all three codes of Enlon in October 2008.
"We are pleased to reintroduce these products, providing health care professionals with access to additional options," said Steve Thornton, CEO Bioniche Pharma.
According to IMS data, 2007 sales of Enlon and Enlon-Plus totalled $2,727,000 and 307,000 units.
Enlon is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. Enlon is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage.
Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products.